Cambridge has been at the forefront of emerging game-changing fields such as precision medicine, AI/machine learning in healthcare and medical robotics as they have emerged from academic theory to practical application, leading to the highest proportion per capita of start-ups in the UK.
life sciences & healthcare:
scaling up
Cambridge has been at the forefront of emerging game-changing fields such as precision medicine, AI/machine learning in healthcare and medical robotics as they have emerged from academic theory to practical application, leading to the highest proportion per capita of start-ups in the UK.
Cambridge has the right combination of a world-leading biomedical research university, ambitious young talent, patient capital and experienced leaders required for a thriving biotech ecosystem
Dr Jason Mellad
CEO and Co-founder, Start Codon Ltd
Cambridge has the right combination of a world-leading biomedical research university, ambitious young talent, patient capital and experienced leaders required for a thriving biotech ecosystem
Dr Jason Mellad
CEO and Co-founder, Start Codon Ltd
Cambridge Enterprise, one of Europe’s leading technology transfer offices, provides funding and intellectual property support at early stages, with University of Cambridge spin-outs raised over $2Bn capital between 2013 and 2017, topping the global list.
congenica.com
Enabling Genomic Medicine
Congenica is a digital health company enabling automated analysis and interpretation of complex genomic data, empowering health professionals to provide life-changing answers that transform the lives of patients and their families.
Congenica is building a future where genomics is fully integrated into healthcare so that personalized decisions and treatments, guided by genomic information, can be routinely used to improve health and wellness around the world
David Atkins, PhD, CEO
petmedix.com
Elevating Expectations in Petcare
PetMedix is bringing the very best of human antibody science to veterinary medicine. Using its proprietary transgenic platforms, PetMedix is discovering and developing novel therapeutic antibodies for dogs and for cats to address a broad range of underserved conditions.
As the crucible for some of the most important antibody discoveries and developments over the past 40 years, Cambridge is the perfect place to bring this world-leading science to our beloved pets. The talent, expertise, and opportunity here is driving our ability to transform animal health.
Dr Thomas Weaver, Founder and Chief Executive Officer
The Cambridge cluster has an unparalleled track record for global growth companies, creating 16 unicorns ($1bn valuation) to date, including Arm, CAT, CMR Surgical and Solexa. Access to venture capital (VC) underpins wider cluster growth. Cambridge Innovation Capital, the preferred investor of the University of Cambridge, has raised £275m to date, forming part of a vibrant Cambridge VC ecosystem which has raised $1.1bn in venture capital funds in the past 2 years, including global investors from the US, the EU and Asia.
Cambridge is the place where the three essential pillars of world leading research; investment; and talent co-locate and collaborate at scale to deliver global impact
Tony Jones, One Nucleus
View Life sciences & healthcare champions
Notable recent highlights
Cambridge Immunity Experimental Medicine Unit
The proposed Immunity Experimental Medicine Unit (iEMU) will enable human experimental medicine studies into COVID-19, accelerating the delivery of vaccines, antivirals and other therapies to the clinic. The proposal is supported by GlaxoSmithKline and AstraZeneca and will play a key part of supporting the pharmaceutical and biotechnology industries.
PerkinElmer acquires Horizon Discovery
Sanofi completes Kymab acquisition
Case study
Developing a new and differentiated class of therapeutics based on proprietary bicyclic peptide (Bicycle®) technology.
Creating the next advance against cancerOther needs for this sector
Cambridge& is here to help
A warm welcome to Cambridge&. We look forward to working with you in accessing the Greater Cambridge ecosystem, to support your plans for locating, partnering and/or scaling here. Cambridge is a safe place to do risky things – for the good of the world.
If you would like to discuss anything please send me a message through the form or give me a call on +44 (0) 7585 290733
Best wishes
Duncan
Duncan McCunn
CEO
Cambridge&